Showing 1 to 2 of 2 results


Immunotherapy Shows Promise in Treating Mismatch Repair Deficient Cancers
A clinical trial at Memorial Sloan Kettering showed that immunotherapy was highly effective in treating mismatch repair deficient (MMRd) cancers, potentially eliminating the need for surgery, chemotherapy, and radiation for many patients, significantly improving quality of life.
Immunotherapy Shows Promise in Treating Mismatch Repair Deficient Cancers
A clinical trial at Memorial Sloan Kettering showed that immunotherapy was highly effective in treating mismatch repair deficient (MMRd) cancers, potentially eliminating the need for surgery, chemotherapy, and radiation for many patients, significantly improving quality of life.
Progress
44% Bias Score

Shared Neoantigens in Endometrial Cancers Suggest Potential for Nous-209 Vaccine
An Italian study found that endometrial cancers with mismatch repair deficiency share many neoantigens with colon and stomach cancers, suggesting the potential use of the existing Nous-209 therapeutic vaccine; 80% of 35 patients showed at least one neoantigen present in Nous-209.

Shared Neoantigens in Endometrial Cancers Suggest Potential for Nous-209 Vaccine
An Italian study found that endometrial cancers with mismatch repair deficiency share many neoantigens with colon and stomach cancers, suggesting the potential use of the existing Nous-209 therapeutic vaccine; 80% of 35 patients showed at least one neoantigen present in Nous-209.
Progress
20% Bias Score
Showing 1 to 2 of 2 results